September 2, 2015
FOR IMMEDIATE RELEASE
September 2, 2015
WASHINGTON, DC—On September 2, 2015, the Patent Trial and Appeal Board (PTAB) declined to institute an inter partes review (IPR) of a patent held by Finnegan client Biogen MA that covers the multiple sclerosis drug Tecfidera®. The IPR petition was filed by the Coalition for Affordable Drugs V (CFAD), a group of hedge funds managed by Kyle Bass.
In its written decision, the PTAB denied institution on all grounds, stating that petitioner CFAD failed to establish a likelihood that any of the challenged claims were unpatentable. This decision comes just three weeks after Finnegan filed a preliminary response on behalf of patent owner Biogen.
The case is Petition for Inter Partes Review by Coalition for Affordable Drugs V LLC, IPR2015-01136, PTAB.
Contacts
James B. Monroe, Managing Partner
james.monroe@finnegan.com
Finnegan is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, copyright, and trade secret law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to European patent oppositions, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. Follow us on LinkedIn and Twitter.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.